BrainsWay FY2024 EPS Forecast Boosted by HC Wainwright

BrainsWay Ltd. (NASDAQ:BWAYFree Report) – Stock analysts at HC Wainwright raised their FY2024 earnings per share (EPS) estimates for BrainsWay in a research report issued to clients and investors on Monday, December 23rd. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.14 for the year, up from their previous forecast of $0.06. HC Wainwright currently has a “Buy” rating and a $16.00 target price on the stock. The consensus estimate for BrainsWay’s current full-year earnings is $0.06 per share. HC Wainwright also issued estimates for BrainsWay’s Q4 2024 earnings at $0.06 EPS, Q1 2025 earnings at $0.06 EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.10 EPS and FY2025 earnings at $0.32 EPS.

BrainsWay (NASDAQ:BWAYGet Free Report) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.04 EPS for the quarter, beating the consensus estimate of $0.01 by $0.03. The business had revenue of $10.50 million during the quarter, compared to analysts’ expectations of $10.07 million. BrainsWay had a net margin of 3.88% and a return on equity of 3.52%. During the same period in the previous year, the business posted ($0.01) EPS.

Separately, Northland Securities lifted their price objective on BrainsWay from $11.00 to $12.50 and gave the company an “outperform” rating in a research note on Thursday, October 3rd.

View Our Latest Research Report on BWAY

BrainsWay Price Performance

Shares of BrainsWay stock opened at $9.35 on Wednesday. BrainsWay has a 1 year low of $4.61 and a 1 year high of $10.98. The stock has a market cap of $175.90 million, a PE ratio of 93.51 and a beta of 1.23. The firm has a fifty day moving average price of $9.84 and a 200 day moving average price of $8.26.

Hedge Funds Weigh In On BrainsWay

Several institutional investors have recently made changes to their positions in BWAY. Acadian Asset Management LLC boosted its holdings in BrainsWay by 48.1% during the second quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock worth $1,567,000 after buying an additional 84,371 shares in the last quarter. Good Life Advisors LLC raised its position in shares of BrainsWay by 65.5% in the third quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock worth $516,000 after acquiring an additional 22,080 shares during the period. Perritt Capital Management Inc purchased a new stake in shares of BrainsWay during the 2nd quarter worth about $121,000. Finally, Rhumbline Advisers grew its position in shares of BrainsWay by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after acquiring an additional 1,695 shares during the period. 30.11% of the stock is owned by hedge funds and other institutional investors.

About BrainsWay

(Get Free Report)

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.

Further Reading

Earnings History and Estimates for BrainsWay (NASDAQ:BWAY)

Receive News & Ratings for BrainsWay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BrainsWay and related companies with MarketBeat.com's FREE daily email newsletter.